GeNeuro Will Contribute Its Expertise in Human Endogenous Retroviruses to the €6.8M EU-Funded HERVCOV Precision Medicine Project
20 Juni 2022 - 6:00PM
Business Wire
- R&D subsidiary GeNeuro Innovation, in Lyon, France, was
selected for its unique expertise in human endogenous
retroviruses
- HERVCOV project aims at developing precision medicine and
diagnostic-based therapeutic solutions for patients affected by the
expression of the envelope protein of the W family of human
endogenous retroviruses (W-ENV)
- GeNeuro Innovation will contribute in setting up
industrial-scale diagnostic and therapeutic tools to address W-ENV
related syndromes identified from this multidisciplinary study of a
large panel of molecular, biological and clinical parameters from
patients.
- Initially focused on COVID-19 and post-COVID syndromes, this
study will also provide insights for other W-ENV-associated
diseases, with the objective of delivering novel precision-medicine
solutions based on the analysis of biomarkers, symptoms and disease
progression
- Project funded by the European Commission with a grant of €6.8
million that involves research centers, companies and associations
from Croatia, France, Greece, Italy and Spain
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a
biopharmaceutical company developing new treatments for
neurodegenerative and autoimmune diseases, such as multiple
sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the
long-term consequences of COVID-19 (post-COVID), announces today
that its R&D subsidiary GeNeuro Innovation SAS will be the
industrial R&D partner of the HERVCOV project funded with a
€6.8 million grant from the European Union HORIZON-Health
program.
The HERVCOV project is funded with a grant under the
HORIZON-HLTH-2021-DISEASE call (Personalised medicine and
infectious disease: understanding the individual host response to
viruses) of the European Commission under the Horizon Europe
Framework Program. The partners include Institut National de la
Santé et de la Recherche Médicale (France), Ethniko Kai
Kapodistriako Panepistimio Athinon (Greece), Rome Tor Vergata
University (Italy), Instituto Aragonés de Ciencias de la Salud
(Spain), Fundación Agencia Aragonesa para la Investigación y el
Desarrollo (Spain), GeNeuro Innovation SAS (France), Inserm
Transfert (France), Klinicki Bolnicki Centar Rijeka (Croatia) and
Frascati Scienza (Italy).
“GeNeuro Innovation will collaborate with its multidisciplinary
partners to develop industrial-grade decentralized W-ENV diagnostic
tools, opening the door to personalized treatment in large
populations affected by W-ENV expression, from post-COVID-19 to
other potentially post-viral diseases with overlapping symptoms,
such as Myalgic encephalomyelitis/chronic fatigue syndrome
(ME/CFS)”, said Hervé Perron, Chief Scientific Officer of
GeNeuro.
“GeNeuro Innovation’s involvement in HERVCOV validates our
leadership in the field of HERVs," said Jesús Martin-Garcia, CEO
of GeNeuro. “We are grateful to be able to participate to this
project with leading EU Research Centers and excited for its
results that may bring novel personalized therapeutic solutions to
patients”.
About HERVCOV
HERVCOV is a collaborative research program benefitting from a
€6.85 million grant from the EU’s HORIZON-HLTH-2021-DISEASE call
(Personalised medicine and infectious disease: understanding the
individual host response to viruses) of the European Commission
under the Horizon Europe Framework Program. The research consortium
comprises research centers from 5 EU countries (INSERM (Institut
National De La Santé Et De La Recherche Médicale and INSERM
TRANSFERT SA, France ; Ethniko Kai Kapodistriako Panepistimio
Athinon, Greece; Universita Degli Studi Di Roma Tor Vergata and
Associazione Frascati Scienza, Italy ; Instituto Aragones De
Ciencias De La Salud, Spain; and Klinicki Bolnicki Centar Rijeka ,
Croatia, together with GeNeuro Innovation.
About GeNeuro
GeNeuro‘s mission is to develop safe and effective treatments
against neurological disorders and autoimmune diseases, such as
multiple sclerosis, by neutralizing causal factors encoded by
HERVs, which represent 8% of human DNA.
GeNeuro is based in Geneva, Switzerland and has R&D
facilities in Lyon, France. It owns rights to 17 patent families
protecting its technology.
For more information, visit: www.geneuro.com
Disclaimer: This press release contains certain forward -
looking statements and estimates concerning GeNeuro’s financial
condition, operating results, strategy, projects and future
performance and the markets in which it operates. Such
forward-looking statements and estimates may be identified by
words, such as “anticipate,” “believe,” “can,” “could,” “estimate,”
“expect,” “intend,” “is designed to,” “may,” “might,” “plan,”
“potential,” “predict,” “objective,” “should,” or the negative of
these and similar expressions. They incorporate all topics that are
not historical facts. Forward looking statements, forecasts and
estimates are based on management’s current assumptions and
assessment of risks, uncertainties and other factors, known and
unknown, which were deemed to be reasonable at the time they were
made but which may turn out to be incorrect. Events and outcomes
are difficult to predict and depend on factors beyond the company’s
control. Consequently, the actual results, financial condition,
performances and/or achievements of GeNeuro or of the industry may
turn out to differ materially from the future results, performances
or achievements expressed or implied by these statements, forecasts
and estimates. Owing to these uncertainties, no representation is
made as to the correctness or fairness of these forward-looking
statements, forecasts and estimates. Furthermore, forward-looking
statements, forecasts and estimates speak only as of the date on
which they are made, and GeNeuro undertakes no obligation to update
or revise any of them, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220620005449/en/
GeNeuro Jesús Martin-Garcia Chairman and CEO +41 22 552
4800 investors@geneuro.com
NewCap Louis-Victor Delouvrier / Mathilde Bohin
(investors) +33 1 44 71 98 52 Arthur Rouillé (media) +33 1 44 71 94
98 geneuro@newcap.eu
GeNeuro (EU:GNRO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
GeNeuro (EU:GNRO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024